Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Creswell, Jacob ^a   Codlin, Andrew J ^b   Andre, Emmanuel ^c   Micek, Mark A ^d,e   Bedru, Ahmed ^f   Carter, E J ^g   Yadav, Rajendra Prasad ^h   Mosneaga, Andrei ⁱ   Rai, Bishwa ^j   Banu, Sayera ^k   Brouwer, Miranda ^l   Blok, Lucie ^m   Sahu, Suvanand ^a   Ditiu, Lucica ^a  

^a Stop TB Partnership   (Switzerland)

^b Interactive Research Development   (Pakistan)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d HEALTH ALLIANCE INTERNATIONAL   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f Project HOPE   (Malawi)

^g BROWN UNIVERSITY   (United States)

^h WHO   (Cambodia)

ⁱ Center for Health Policies and Studies   (Moldova)

^j INTERNATIONAL ORGANIZATION FOR MIGRATION   (Switzerland)

^k INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^l PHTB Consult   (Netherlands)

^m ROYAL TROPICAL INSTITUTE   (Netherlands)

more..

Author keywords

Case detection; Innovation; New diagnostics; Tuberculosis; Xpert MTB RIF

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; VIRUS RNA; ZIDOVUDINE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; DRUG EFFICACY; ETHIOPIA; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNITY; IMMUNOLOGICAL RECOVERY; MAJOR CLINICAL STUDY; MALE; VIRAL PHENOMENA AND FUNCTIONS; VIREMIA; VIRUS SUPPRESSION; ALGORITHM; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DEVICES; HEALTH CARE DELIVERY; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, PULMONARY;

ADULT; ALGORITHMS; ANTIBIOTICS, ANTITUBERCULAR; DRUG RESISTANCE, BACTERIAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONALITY; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, PULMONARY;

EID: 84892899108     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-2     Document Type: Article

References (40)

1. World Health Organization Global Tuberculosis Report 2013 2012, Geneva, Switzerland: World Health Organization, World Health Organization.
2. World Health Organization Policy Statement: Automated real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System 2011, Geneva, Switzerland: World Health Organization, World Health Organization.
3. World Health Organization Rapid Implementation of the Xpert MTB/RIF diagnostic test 2011, Geneva, Switzerland: World Health Organization, World Health Organization.
4. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363(11):1005-1015.
5. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013, 1:CD009593.
6. WHO monitoring of MTB/RIF roll-out. [http://www.who.int/tb/laboratory/mtbrifrollout/en/index.html].
7. Bates M, O'Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C, Kasonde R, Mulota P, Mzyece J, Chomba M, Mukonda L, Mumba M, Kapata N, Rachow A, Clowes P, Hoelscher M, Mwaba P, Zumla A. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis 2012, 13(1):36-42.
8. Lawn SD, Kerkhoff AD, Vogt M, Wood R. High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay. J Acquir Immune Defic Syndr 2012, 60(3):289-294.
9. Walters E, Gie RP, Hesseling AC, Friedrich SO, Diacon AH, Gie RP. Rapid diagnosis of pediatric intrathoracictuberculosis from stool samples using the Xpert MTB/RIF assay: a pilot study. Pediatr Infect Dis J 2012, 31(12):1316.
10. Friedrich SO, von Groote-Bidlingmaier F, Diacon AH. Xpert MTB/RIF assay for the diagnosis of pleural tuberculosis. J Clin Microbiol 2011, 49(12):4341-4342.
11. Zar HJ, Workman L, Isaacs W, Munro J, Black F, Eley B, Allen V, Boehme CC, Zemanay W, Nicol MP. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis 2012, 55(8):1088-1095.
12. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. Diagnostic performance of Genotype® MTBDRplus Version 2 line probe assay is equivalent to the Xpert® MTB/RIF assay. J Clin Microbiol 2012, 50(11):3712-3716.
13. Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA. An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 2012, 74(2):207-209.
14. Dheda K, Ruhwald M, Theron G, Peter J, Yam WC. Point-of-care diagnosis of tuberculosis: past, present and future. Respirology 2012, 18(2):217-232.
15. Peters D, Grant T, Jonny P, Keertan D. Should Xpert® MTB/RIF be rolled out in low-income countries? [correspondence]. Int J Tuberc Lung Dis 2012, 16(5):702-703.
16. Trébucq A, Harries AD, Rieder HL. In reply to 'Should Xpert® MTB/RIF be rolled out in low-income countries?'. Int J Tuberc Lung Dis 2012, 16(5):703-704.
17. Singh JA, Bhan A. The ethics of national tuberculosis programmes in low-income countries not rolling out Xpert® MTB/RIF. Int J Tuberc Lung Dis 2011, 15(12):1563.
18. Dowdy DW, Cattamanchi A, Steingart KR, Pai M. Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med 2011, 8(7):e1001063.
19. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, Davis JL, Whitelaw A, Nicol MP, Gler MT, Khaliqov A, Zamudio C, Perkins MD, Boehme CC, Cobelens F. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011, 8(11):e1001120.
20. Evans CA. GeneXpert-a game-changer for tuberculosis control?. PLoS Med 2011, 8(7):e1001064.
21. Small P, Pai M. Tuberculosis diagnosis - time for a game change. N Engl J Med 2010, 363:1070-1071.
22. Denkinger CM, Grenier J, Minion J, Pai M. Promise versus reality: optimism bias in package inserts for tuberculosis diagnostics. J Clin Microbiol 2012, 50(7):2455-2461.
23. TB REACH Website. [http://www.stoptb.org/global/awards/tbreach/about.asp.].
24. Public-private partnership announces immediate 40 percent cost reduction for rapid TB test. [http://www.usaid.gov/news-information/press-releases/public-private-partnership-announces-immediate-40-percent-cost.].
25. Cepheid announces update on Xpert® test availability. [http://ir.cepheid.com/releasedetail.cfm?releaseid=732096.].
26. Trébucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, Boillot F, Detjen A, Fujiwara PI, Graham SM, Monedero I, Rusen ID, Rieder HL. Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?. Int J Tuberc Lung Dis 2011, 15:1567-1572.
27. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M, Zumla A. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013, 13:349-361.
28. Stevens W. " South Africa's " Reality Check" >1 million Xpert tests." Global laboratory initiative. " Xpert SMS - introducing automated MTB/RIF reporting into running projects. 5th Annual GLI Meeting Advances in TB Diagnostic Services 2013, Annecy, France: Transforming TB Care & Control, http://www.stoptb.org/wg/gli/assets/html/GLI5/GLI%205th%20meeting%20SA%20perspective%20v7.pdf.
29. World Health Organization Systematic screening for active tuberculosis - principles and recommendations 2013, Geneva, Switzerland: World Health Organization, World Health Organization.
30. Codlin AJ, Javaid M, Qazi F, Khan MS. Novel methodology to assess sputum smear microscopy quality in private laboratories. BMC Infect Dis 2012, 12:331.
31. World Health Organization Policy Guidance on Xpert MTB/RIF testing 2013, Geneva, Switzerland: World Health Organization, http://www.stoptb.org/wg/gli/assets/documents/WHO%20Policy%20Statement%20on%20Xpert%20MTB-RIF%202013%20pre%20publication%2022102013.pdf, World Health Organization.
32. GeneXpertDx System: Operator Manual Software version 4.0 e-dok.rm.dk/e-dok/e_702615.nsf/$CXIV/ATTACH-RMAP-8QVAXS/$FILE/Operator%20Manual%20Rev%20C[1].1%204.0%20Version%20GX%20Dx%20Operator%20Manual_EN%20Mar11.pdf.
33. Khan A. " XpertSMS - introducing automated MTB/RIF reporting into running rojects." Global laboratory initiative. " Xpert SMS - introducing automated MTB/RIF reporting into running projects. 5th Annual GLI Meeting Advances in TB Diagnostic Services 2013, Annecy, France: Transforming TB Care & Control, http://www.stoptb.org/wg/gli/assets/html/GLI5/GLI_2013_XpertSMS_IRD_v5.pdf.
34. Varaine F, Ardizzoni E. " Xpert MTB/RIF ® implementation in MSF projects: First results." Global Laboratory Initiative. 4th Annual GLI Meeting/Consultation of the WHO/GLI SRL Network/Early Implementers Meeting on Xpert MTB/RIF roll-out, Annecy, France, April 17-19, 2012 http://www.stoptb.org/wg/gli/assets/html/day%202/Varaine%20-%20MSF%20projects.pdf.
35. World Health Organization Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and response 2010, Geneva, Switzerland: World Health Organization, World Health Organization.
36. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med 2012, 9(9):e1001306.
37. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K, for the TB-NEAT team Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2013, doi:10.1016/S0140-6736(13)62073-5. [Epub ahead of print], for the TB-NEAT team.
38. Denkinger CM, Nicolau I, Ramsay A, Chedore P, Pai M. Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics?. Eur Respir J 2013, 42(2):544-547. doi:10.1183/09031936.00081113.
39. Global laboratory initiative. 4th annual GLI meeting/consultation of the WHO/GLI SRL network/early implementers meeting on Xpert MTB/RIF roll-out, Annecy, France, April 17-19, 2012. [http://www.stoptb.org/wg/gli/assets/html/4th%20GLI%20meeting%2017-19%20April%202012%20AGENDA.htm.].
40. World Health Organization Definitions and Reporting Framework for Tuberculosis - 2013 revision 2013, Geneva, Switzerland: World Health Organization, World Health Organization.